Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
104.00    0.80 (0.78%)
Bid:
100.20
Ask:
105.80
Spread: 5.60 (5.589%)
Market Cap: £170.50m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Disposal

5 Jan 2009 11:17

RNS Number : 0853L
Yule Catto & Co PLC
05 January 2009
 

5 January 2009

Yule Catto & Co plc

Disposal of Oxford Chemicals Limited

Yule Catto & Co plc ("the Group"), an international producer of specialty chemicals used in a wide range of industries including pharmaceuticals, FMCG, paints and adhesivesis pleased to announce that it has exchanged conditional contracts with Frutarom (UK) Limited for the sale of the business and assets of Oxford Chemicals Limited for a consideration of £8.25 million.  The consideration will be paid in full in cash at completion.

The completion of the sale is conditional on regulatory approval for the transfer of operational licences and compliance with employee information and consultation requirements.

The proceeds of the sale will be used to reduce the Group's borrowings.

Oxford Chemicals develops, manufactures and supplies high impact aroma chemicals and other specialty aroma chemicals In the twelve months to 31 December 2007 it had sales of £9.7 million, an operating profit of £0.6 million and gross assets of £6.4 million.

The Oxford Chemicals management team led by Anthony Weston will continue to run the business.

Adrian Whitfield, Chief Executive, commented:

"We are now in the final stages of implementing our stated strategy of divesting the Impact Chemicals division, with gross proceeds to date reaching some £63 million."

Recent update

Yule Catto issued an update on 29 December 2008, the full text of which is repeated below.

Yule Catto & Co plc ("the Group") is pleased to announce that it has signed a new three year £30 million revolving loan facility with its principal banks, HSBC and Barclays. This loan replaces its existing revolving bank loan facility maturing in November 2009.

During the course of this re-financing, the Board has been carefully considering the capital structure of the Group. Whilst much progress has been made on the deleveraging of the balance sheet, with £55 million of gross proceeds received from the sale of three of our five Impact Chemicals businesses*, the balance sheet remains a core focus of the Board and it aims to reduce outstanding net debt to below £100 million over the next twelve to twenty four months. The Board believes this is consistent with the Group's objectives, including its financial commitments to the Group's UK pension fund.

Accordingly, and in light of the current financial environment and economic uncertainty, the Board has additionally decided to suspend the payment of dividends until such time as net debt is nearer to its overall target and at which time the business environment and financial market conditions may well have improved. The Board anticipates reverting to the payment of a dividend within two years.

At the time the Group recommences the payment of a dividend, the Board anticipates rebasing it to a level determined by comparison with its peer group and which will allow an appropriate free cash flow to suit the Group's circumstances.

The Board is also pleased to confirm that for 2008 the Group still expects to deliver underlying earnings before tax modestly ahead of last year, despite the current difficult economic conditions particularly in the UK and Continental Europe. The Board believes it is too early at this time, given the prevailing economic uncertainty, to offer any firm guidance on the outturn for 2009. The Group's Impact Chemicals and Pharma Chemicals businesses should benefit next year from recent restructuring. Within our Polymer Chemicals business we anticipate the performance of our Asian and Middle East businesses to be more robust than that of our European businesses, due to local market conditions and a more resilient demand profile from our targeted markets. In addition, the current relative weakness of Sterling against the Dollar, Euro and Malaysian Ringgit, should it continue, will assist the reported Sterling earnings for a number of our businesses.

The Group continues to look at ways to improve efficiency and minimise costs. We currently have a number of initiatives in hand to do this, both within Europe and the rest of the world. 

These are exceptional times, with a high degree of market uncertainty and a very difficult environment for funding. Having completed £55 million of divestments* and put in place a new revolving loan, the Board believes that, together with internal actions to conserve cash and the suspension of the dividend, Yule Catto is now well placed to weather these conditions.

(* before the disposal of Oxford Chemicals announced today)

- Ends -

For further information, please contact:

 

Yule Catto & Co plc 
Adrian Whitfield, Chief Executive 
David Blackwood, Group Finance Director
 
01279 442791
Hogarth Partnership
John Olsen
Andrew Jaques
Ian Payne
020 7357 9477
07770 272082

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISILFLLLSIEIIA
Date   Source Headline
3rd May 20181:38 pmRNSHolding(s) in Company
2nd May 20184:29 pmRNSDirector/PDMR Shareholding
26th Apr 20182:23 pmRNSResult of AGM
26th Apr 20187:00 amRNSQ1 Trading update
9th Apr 20184:54 pmRNSDirector Declaration
27th Mar 20181:03 pmRNSDirector/PDMR Shareholding
27th Mar 20181:01 pmRNSDirector/PDMR Shareholding
26th Mar 20184:55 pmRNSAnnual Financial Report
8th Mar 20184:39 pmRNSDirector/PDMR Shareholding
8th Mar 20184:37 pmRNSDirector/PDMR Shareholding
5th Mar 20182:43 pmRNSDirector/PDMR Shareholding
1st Mar 20187:00 amRNSResults for the year ended 31 December 2017
12th Feb 201810:27 amRNSDirector Declaration
1st Feb 20187:00 amRNSCompletion of the acquisition of BASF Pischelsdorf
2nd Jan 20187:00 amRNSDisposal of Synthomer Leuna Gmbh facility
13th Dec 20172:55 pmRNSDirector Declaration
4th Dec 20175:31 pmRNSHolding(s) in Company
27th Nov 20179:29 amRNSHolding(s) in Company
10th Nov 20179:40 amRNSDirectorate Change
9th Nov 201710:03 amRNSDirector/PDMR Shareholding
6th Nov 20177:00 amRNSQ3 Trading update
9th Oct 20179:23 amRNSDirector Declaration
28th Sep 20177:00 amRNSAcquisition of BASF Pischelsdorf
18th Sep 20172:00 pmRNSHolding(s) in Company
17th Aug 201712:54 pmRNSHolding(s) in Company
8th Aug 20177:00 amRNSInterim Results for the 6 months ended 30 Jun 2017
1st Aug 20173:57 pmRNSHolding(s) in Company
10th Jul 201710:33 amRNSDirector/PDMR Shareholding
9th Jun 20173:14 pmRNSDirector/PDMR Shareholding
8th May 201712:40 pmRNSDirector/PDMR Shareholding
8th May 201712:24 pmRNSDirector/PDMR Shareholding
27th Apr 20174:05 pmRNSDirector Declaration
27th Apr 20172:53 pmRNSResult of AGM
27th Apr 20177:00 amRNSQ1 Trading update
27th Mar 20179:54 amRNSAnnual Financial Report
6th Mar 20177:02 amRNSAcquisition of Perstorp Belgium
6th Mar 20177:00 amRNSFinal Results
23rd Feb 20174:31 pmRNSAmendment TR-1 notification
8th Feb 20174:13 pmRNSHolding(s) in Company
6th Feb 201711:48 amRNSHolding(s) in Company
20th Jan 20177:00 amRNSQ4 and FY trading update
13th Dec 201610:57 amRNSHolding(s) in Company
1st Dec 20167:00 amRNSCapital Markets Day
28th Nov 20169:51 amRNSHolding(s) in Company
18th Nov 20164:56 pmRNSHolding(s) in Company
16th Nov 201610:15 amRNSHolding(s) in Company
10th Nov 20162:23 pmRNSHolding(s) in Company
9th Nov 20164:18 pmRNSDirector/PDMR Shareholding
9th Nov 20167:00 amRNSQ3 Trading update
3rd Oct 20162:11 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.